Aclaris Therapeutics, Inc.
ACRS · XNASCIK 1557746fmd_03H93ZDXZ56110PERRPKCVW4MGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 2 | 6 | 4 | 6 | 7 | 30 | 31 | 19 | 8 |
| Cost of revenue | – | 1 | 4 | 4 | 5 | 5 | 4 | 3 | 3 | 2 |
| Gross profit | – | 0 | 3 | 0 | 1 | 2 | 26 | 28 | 16 | 6 |
| Research and development | 33 | 36 | 61 | 64 | 29 | 44 | 78 | 98 | 34 | 53 |
| Selling, general and administrative | 15 | 19 | 26 | 28 | – | – | – | – | – | – |
| Total operating expenses | 49 | 73 | 139 | – | – | – | – | – | – | – |
| Operating income | (49) | (54) | (85) | (111) | (51) | (90) | (90) | (97) | (142) | (76) |
| Interest and investment income | – | – | – | – | – | – | – | 9 | 8 | 8 |
| Other non-operating income (expense) | 0 | 2 | 3 | (2) | (0) | (1) | 3 | 9 | 10 | 11 |
| Income before taxes | (48) | (70) | (82) | (114) | (51) | (91) | (87) | (89) | (132) | (65) |
| Income tax expense | – | (2) | – | – | (0) | – | – | (0) | – | – |
| Net income from continuing operations | – | (52) | (82) | (114) | (51) | (91) | (87) | (88) | – | – |
| Net income | (48) | (69) | (133) | (161) | (51) | (91) | (87) | (88) | (132) | (65) |
| Net income to common shareholders | (48) | (69) | – | – | – | – | – | – | – | – |